Digirad Corp (DRAD, Financial)(30-Year Financial) files its latest 10-K with SEC for the fiscal year ended on December 31, 2019. Digirad Corp develops nuclear technology for mobile cardiovascular imaging for various application. The company commercialized the first nuclear gamma camera and offers its products to doctors' offices and hospitals. Digirad Corp has a market cap of $10.810 million; its shares were traded at around $5.27 with and P/S ratio of 0.10. Digirad Corp had annual average EBITDA growth of 10.50% over the past five years. GuruFocus has detected 3 severe warning signs with Digirad Corp. .
For the last quarter Digirad Corp reported a revenue of $36.1 million, compared with the revenue of $25.93 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $114.2 million, an increase of 9.6% from last year. For the complete 30-year financial data, please go here.. For the last five years Digirad Corp had an average revenue growth rate of 15.5% a year.
The reported loss per diluted share was $2.56 for the year, compared with the earnings per share of $-17.9 in the previous year. The Digirad Corp had an operating margin of -1.1%, compared with the operating margin of -3.42% a year before. The 10-year historical median operating margin of Digirad Corp is -1.44%. The profitability rank of the company is 5 (out of 10).
At the end of the fiscal year, Digirad Corp has the cash and cash equivalents of $1.82 million, compared with $1.55 million in the previous year. The long term debt was $20.1 million, compared with $9.50 million in the previous year. Digirad Corp has a financial strength rank of 3 (out of 10).
At the current stock price of $5.27, Digirad Corp is traded at 87% discount to its historical median P/S valuation band of $40.67. The P/S ratio of the stock is 0.10, while the historical median P/S ratio is 0.76. The stock lost 29.23% during the past 12 months.
For the complete 20-year historical financial data of DRAD, click here.
